COMP <GO>
SMID vs TMO // FORWARD P/E MULTIPLE
Smith-Midland Corporation (NASDAQ) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: SMID 7
— TMO 4
▲ FORWARD P/E MULTIPLE LEADER: SMID
LAST: $22.51 (+0.76%) • MKT CAP: $118.5M
forward-pe
8.0x
LAST: $697.00 (-1.72%) • MKT CAP: $262.22B
forward-pe
36.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SMID VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SMID | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 27.90% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 24.70% | 9.30% | +15.40 | SMID | /roic <GO> |
| EV/EBITDA & P/E Valuation | 4.8x | 30.4x | -25.60 | SMID | /valuation <GO> |
| Free Cash Flow Yield | 4.19% | 2.40% | +1.79 | SMID | /fcf-yield <GO> |
| Operating Margin | 18.20% | 17.40% | +0.80 | SMID | /operating-margins <GO> |
| Net Profit Margin | 13.40% | 15.10% | -1.70 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | 19.00% | 3.90% | +15.10 | SMID | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.24% | -0.24 | TMO | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.05 | 4.50 | +0.55 | SMID | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.7 | 62.9 | -13.20 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.94 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 8.0x | 36.3x | -28.30 | SMID | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $118.5M | $262.22B | -$262.10B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SMID REV | TMO REV | SMID GROSS % | TMO GROSS % | SMID FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $93.4M | $44.56B | 27.9% | — | $5.0M | $6.29B |
| FY 2024 | $78.5M | $42.88B | 25.5% | — | -$1.0M | $7.27B |
| FY 2023 | $59.6M | $42.86B | — | — | $7.7M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SMID // BETA —
TMO // BETA 0.94